Angiopoietin-1 and -2 exert antagonistic functions in tumor angiogenesis, yet both induce lymphangiogenesis

Cancer Research

Volumn 71, Issue 17, 2011, Pages 5717-5727

  Fagiani, Ernesta ^a   Lorentz, Pascal ^a   Kopfstein, Lucie ^a   Christofori, Gerhard ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CAPILLARY DENSITY; CARCINOGENESIS; CELL FUNCTION; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKOCYTE; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; MOUSE; NONHUMAN; PANCREAS ISLET CELL TUMOR; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR MODEL; VASODILATATION;

ANGIOPOIETIN-1; ANGIOPOIETIN-2; ANIMALS; CELLS, CULTURED; HUMANS; LYMPHANGIOGENESIS; MICE; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; PROMOTER REGIONS, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80052211625     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-4635     Document Type: Article

References (49)

1. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64. (Pubitemid 26272076)
2. Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 2010;10:505-14.
3. Fischer C, Mazzone M, Jonckx B, Carmeliet P. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?Nat Rev Cancer 2008;8:942-56.
4. Lohela M, Bry M, Tammela T, Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 2009;21:154-65.
5. Huang H, Bhat A, Woodnutt G, Lappe R. Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 2010;10:575-85.
6. Augustin HG, Koh GY, Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 2009;10:165-77.
7. Fiedler U, Krissl T, Koidl S, Weiss C, Koblizek T, Deutsch U, et al. Angiopoietin-1 and angiopoietin-2 share the same binding domains in the Tie-2 receptor involving the first Ig-like loop and the epidermal growth factor-like repeats. J Biol Chem 2003;278:1721-7. (Pubitemid 36801406)
8. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion- trap expression cloning. Cell 1996;87:1161-9. (Pubitemid 27010100)
9. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003;9: 685-93. (Pubitemid 36749217)
10. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997;277:55-60. (Pubitemid 27450643)
11. Kim I, Kim JH, Moon SO, Kwak HJ, Kim NG, Koh GY. Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 30-kinase/Akt signal transduction pathway. Oncogene 2000;19:4549-52.
12. Daly C, Pasnikowski E, Burova E, Wong V, Aldrich TH, Griffiths J, et al. Angiopoietin-2 functions as an autocrine protective factor in stressed endothelial cells. Proc Natl Acad Sci U S A 2006;103:15491-6. (Pubitemid 44625619)
13. Machein MR, Knedla A, Knoth R, Wagner S, Neuschl E, Plate KH. Angiopoietin-1 promotes tumor angiogenesis in a rat glioma model. Am J Pathol 2004;165:1557-70. (Pubitemid 39435155)
14. Ahmad SA, Liu W, Jung YD, Fan F, Wilson M, Reinmuth N, et al. The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer. Cancer Res 2001;61:1255-9. (Pubitemid 34292536)
15. Etoh T, Inoue H, Tanaka S, Barnard GF, Kitano S, Mori M. Angiopoietin- 2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. Cancer Res 2001;61:2145-53. (Pubitemid 32692040)
16. Hu B, Guo P, Fang Q, Tao HQ, Wang D, Nagane M, et al. Angiopoietin- 2 induces human glioma invasion through the activation of matrix metalloprotease-2. Proc Natl Acad Sci U S A 2003;100:8904-9. (Pubitemid 36899196)
17. Yu Q, Stamenkovic I. Angiopoietin-2 is implicated in the regulation of tumor angiogenesis. Am J Pathol 2001;158:563-70. (Pubitemid 32158617)
18. Nasarre P, Thomas M, Kruse K, Helfrich I, Wolter V, Deppermann C, et al. Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Cancer Res 2009;69:1324-33.
19. Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenicmice expressing recombinant insulin/simian virus 40 oncogenes. Nature 1985;315:115-22. (Pubitemid 15064530)
20. Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 1998;392:190-3. (Pubitemid 28162793)
21. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339:58-61. (Pubitemid 19115892)
22. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737-44.
23. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999;284:808-12. (Pubitemid 29291347)
24. Schomber T, Zumsteg A, Strittmatter K, Crnic I, Antoniadis H, Littlewood- Evans A, et al. Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis. Mol Cancer Ther 2009;8: 55-63.
25. Pietras K, Hanahan D. A multitargeted, metronomic, and maximumtolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 2005;23:939-52. (Pubitemid 46202314)
26. Compagni A, Wilgenbus P, Impagnatiello MA, Cotten M, Christofori G. Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Res 2000;60:7163-9. (Pubitemid 32059199)
27. Gannon G, Mandriota SJ, Cui L, Baetens D, Pepper MS, Christofori G. Overexpression of vascular endothelial growth factor-A165 enhances tumor angiogenesis but not metastasis during beta-cell carcinogenesis. Cancer Res 2002;62:603-8. (Pubitemid 34106438)
28. Baluk P, Morikawa S, Haskell A, Mancuso M, McDonald DM. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol 2003;163:1801-15. (Pubitemid 37310012)
29. Tammela T, Saaristo A, Lohela M, Morisada T, Tornberg J, Norrmen C, et al. Angiopoietin-1 promotes lymphatic sprouting and hyperplasia. Blood 2005;105:4642-8. (Pubitemid 40807283)
30. Morisada T, Oike Y, Yamada Y, Urano T, Akao M, Kubota Y, et al. Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation. Blood 2005;105:4649-56. (Pubitemid 40807284)
31. Gale NW, Thurston G, Hackett SF, Renard R, Wang Q, McClain J, et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell 2002;3:411-23.
32. Lobov IB, Brooks PC, Lang RA. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci U S A 2002;99:11205-10. (Pubitemid 34920903)
33. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000;60:2178-89. (Pubitemid 30225181)
34. Grunewald M, Avraham I, Dor Y, Bachar-Lustig E, Itin A, Jung S, et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 2006;124:175-89. (Pubitemid 43069318)
35. Zentilin L, Tafuro S, Zacchigna S, Arsic N, Pattarini L, Sinigaglia M, et al. Bone marrow mononuclear cells are recruited to the sites of VEGF-induced neovascularization but are not incorporated into the newly formed vessels. Blood 2006;107:3546-54.
36. De Palma M, Murdoch C, Venneri MA, Naldini L, Lewis CE. Tie2- expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. Trends Immunol 2007;28:519-24.
37. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006;124:263-6. (Pubitemid 43121975)
38. Crnic I, Strittmatter K, Cavallaro U, Kopfstein L, Jussila L, Alitalo K, et al. Loss of neural cell adhesion molecule induces tumor metastasis by up-regulating lymphangiogenesis. Cancer Res 2004;64: 8630-8. (Pubitemid 39552076)
39. Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 2001;20:672-82. (Pubitemid 32167632)
40. Kopfstein L, Veikkola T, Djonov VG, Baeriswyl V, Schomber T, Strittmatter K, et al. Distinct roles of vascular endothelial growth factor-D in lymphangiogenesis and metastasis. Am J Pathol 2007;170:1348-61. (Pubitemid 47339341)
41. Suri C, McClain J, Thurston G, McDonald DM, Zhou H, Oldmixon EH, et al. Increased vascularization in mice overexpressing angiopoietin-1. Science 1998;282:468-71. (Pubitemid 28483672)
42. Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD, et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 1999;286:2511-4.
43. Stratmann A, Risau W, Plate KH. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 1998;153:1459-66. (Pubitemid 28509902)
44. Zhang L, Yang N, Park JW, Katsaros D, Fracchioli S, Cao G, et al. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin- 2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res 2003;63: 3403-12. (Pubitemid 36735901)
45. Cao Y, Sonveaux P, Liu S, Zhao Y, Mi J, Clary BM, et al. Systemic overexpression of angiopoietin-2 promotes tumor microvessel regression and inhibits angiogenesis and tumor growth. Cancer Res 2007;67:3835-44. (Pubitemid 46762171)
46. Fiedler U, Augustin HG. Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol 2006;27:552-8.
47. Inoue M, Hager JH, Ferrara N, Gerber HP, Hanahan D. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 2002;1:193-202. (Pubitemid 41039165)
48. Findley CM, Cudmore MJ, Ahmed A, Kontos CD. VEGF induces Tie2 shedding via a phosphoinositide 3-kinase/Akt dependent pathway to modulate Tie2 signaling. Arterioscler Thromb Vasc Biol 2007;27: 2619-26. (Pubitemid 350158914)
49. Oliner J, Min H, Leal J, Yu D, Rao S, You E, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004;6:507-16. (Pubitemid 39469986)